X-linked adrenoleukodystrophy. (Q34002811)

30 July 2017

1 reference

title

X-linked adrenoleukodystrophy. (English)

1 reference

30 July 2017

3

Gerald V Raymond

1 reference

30 July 2017

Hugo W Moser

1

1 reference

PubMed ID

17342190

30 July 2017

Asif Mahmood

series ordinal

2

1 reference

30 July 2017

1 March 2007

1 reference

Nature Clinical Practice Neurology

30 July 2017

1 reference

30 July 2017

3

1 reference

30 July 2017

3

1 reference

30 July 2017

140-151

1 reference

https://scigraph.springernature.com/pub.10.1038/ncpneuro0421

30 July 2017

0 references

cites work

Mirror expression of adrenoleukodystrophy and adrenoleukodystrophy related genes in mouse tissues and human cell lines

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

Adrenoleukodystrophy. A clinical and pathological study of 17 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

Potential environmental and host participants in the early white matter lesion of adreno-leukodystrophy: morphologic evidence for CD8 cytotoxic T cells, cytolysis of oligodendrocytes, and CD1-mediated lipid antigen presentation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

Adrenomyeloneuropathy: A probable variant of adrenoleukodystrophy I. Clinical and endocrinologic aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

Adrenomyeloneuropathy: a neuropathologic review featuring its noninflammatory myelopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

The dorsal root ganglia in adrenomyeloneuropathy: neuronal atrophy and abnormal mitochondria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

Spectroscopic evidence of cerebral axonopathy in patients with "pure" adrenomyeloneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

MRI and proton MRSI in women heterozygous for X-linked adrenoleukodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

Inducible nitric oxide synthase in the central nervous system of patients with X-adrenoleukodystrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

Adrenoleukodystrophy: correlating MR imaging with CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

Analysis of MRI patterns aids prediction of progression in X-linked adrenoleukodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

Proton MR spectroscopic imaging predicts lesion progression on MRI in X-linked adrenoleukodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

Assessment of adrenoleukodystrophy lesions by high field MRS in non-sedated pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

Dietary erucic acid therapy for X-linked adrenoleukodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

Adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Elongation of very long-chain fatty acids is enhanced in X-linked adrenoleukodystrophy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Fatty acid abnormality in adrenoleukodystrophy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Phospholipids in X-linked adrenoleukodystrophy white matter: fatty acid abnormalities before the onset of demyelination

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Correlation of very long chain fatty acid accumulation and inflammatory disease progression in childhood X-ALD: implications for potential therapies.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

The correlation between biochemical and histopathological findings in adrenoleukodystrophy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Brain gangliosides in adrenoleukodystrophy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Fatty Acid Composition of Human Myelin Proteolipid Protein in Peroxisomal Disorders

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Abnormality of long-chain fatty acids in erythrocyte membrane sphingomyelin from patients with adrenoleukodystrophy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Adrenoleukodystrophy: Elevated C26 fatty acid in cultured skin fibroblasts

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Adrenoleukodystrophy: impaired oxidation of very long chain fatty acids in white blood cells, cultured skin fibroblasts, and amniocytes

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Accumulation and defective beta-oxidation of very long chain fatty acids in Zellweger's syndrome, adrenoleukodystrophy and Refsum's disease variants

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Gene redundancy and pharmacological gene therapy: implications for X-linked adrenoleukodystrophy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Peroxisomal very long-chain fatty acid beta-oxidation in human skin fibroblasts: activity in Zellweger syndrome and other peroxisomal disorders

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Lignoceric acid is oxidized in the peroxisome: implications for the Zellweger cerebro-hepato-renal syndrome and adrenoleukodystrophy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Peroxisomal beta-oxidation: enzymology and molecular biology

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Peroxisomes, lipid metabolism, and peroxisomal disorders

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Molecular cloning of cDNA encoding rat very long-chain acyl-CoA synthetase

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Peroxisomal lignoceroyl-CoA ligase deficiency in childhood adrenoleukodystrophy and adrenomyeloneuropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Role of ALDP (ABCD1) and mitochondria in X-linked adrenoleukodystrophy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Accumulation of very long-chain fatty acids does not affect mitochondrial function in adrenoleukodystrophy protein deficiency

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Increased Synthesis of Hexacosanoic Acid (C26 :0) by Cultured Skin Fibroblasts from Patients with Adrenoleukodystrophy (ALD) and Adrenomyeloneuropathy (AMN)1

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Interactions of a very long chain fatty acid with model membranes and serum albumin. Implications for the pathogenesis of adrenoleukodystrophy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Interactions of very long-chain saturated fatty acids with serum albumin

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Adrenoleukodystrophy: evidence for X linkage, inactivation, and selection favoring the mutant allele in heterozygous cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Adrenoleukodystrophy-related protein can compensate functionally for adrenoleukodystrophy protein deficiency (X-ALD): implications for therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Functional overlap between ABCD1 (ALD) and ABCD2 (ALDR) transporters: a therapeutic target for X-adrenoleukodystrophy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

ABCD1 mutations and the X-linked adrenoleukodystrophy mutation database: role in diagnosis and clinical correlations

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

The gene responsible for adrenoleukodystrophy encodes a peroxisomal membrane protein

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Peroxisomal very long chain fatty acid beta-oxidation activity is determined by the level of adrenodeukodystrophy protein (ALDP) expression

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

The peroxisomal ABC transporter family

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Adrenoleukodystrophy: phenotypic variability and implications for therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

X-linked adrenoleukodystrophy: genes, mutations, and phenotypes

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

The inflammatory myelinopathy of adreno-leukodystrophy: cells, effector molecules, and pathogenetic implications

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Adreno-leukodystrophy: oxidative stress of mice and men.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Spastic paraplegia associated with Addison's disease: adult variant of adreno-leukodystrophy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Nerve conduction studies in adrenomyeloneuropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Peripheral nerve abnormalities in adrenomyeloneuropathy: a clinical and electrodiagnostic study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Evolution of phenotypes in adult male patients with X-linked adrenoleukodystrophy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

X-linked adrenoleukodystrophy in patients with idiopathic addison disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Accurate DNA-based diagnostic and carrier testing for X-linked adrenoleukodystrophy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Cognitive evaluation of neurologically asymptomatic boys with X-linked adrenoleukodystrophy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Clinical Aspects of Adrenoleukodystrophy and Adrenomyeloneuropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Neurophysiological abnormalities in adrenoleukodystrophy carriers. Evidence of different degrees of central nervous system involvement.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Free radical release in C6 glial cells enriched in hexacosanoic acid: implication for X-linked adrenoleukodystrophy pathogenesis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Evidence that oxidative stress is increased in patients with X-linked adrenoleukodystrophy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

The molecular basis of CD1-mediated presentation of lipid antigens

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Methionine metabolism and phenotypic variability in X-linked adrenoleukodystrophy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Adrenoleukodystrophy: new approaches to a neurodegenerative disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Analysis of very long-chain fatty acids using electrospray ionization mass spectrometry

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Identification of female carriers of adrenoleukodystrophy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

The prenatal diagnosis of X-linked adrenoleukodystrophy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Diffusion tensor-based imaging reveals occult abnormalities in adrenomyeloneuropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Magnetization transfer MRI demonstrates spinal cord abnormalities in adrenomyeloneuropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Biochemical effect of intravenous arginine butyrate in X-linked adrenoleukodystrophy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Lovastatin therapy for X-linked adrenoleukodystrophy: clinical and biochemical observations on 12 patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Thyroid hormone induction of the adrenoleukodystrophy-related gene (ABCD2).

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Transduced CD34+ cells from adrenoleukodystrophy patients with HIV-derived vector mediate long-term engraftment of NOD/SCID mice.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Adrenal insufficiency in asymptomatic adrenoleukodystrophy patients identified by very long-chain fatty acid screening

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Clinical and electrophysiological improvement of adrenomyeloneuropathy with steroid treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil"

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Experience on therapy of adrenoleukodystrophy and adrenomyeloneuropathy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

A two-year trial of oleic and erucic acids ("Lorenzo's oil") as treatment for adrenomyeloneuropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo's oil.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Male donor-derived cells in the brains of female sex-mismatched bone marrow transplant recipients: a Y-chromosome specific in situ hybridization study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Immunoablation does not delay the neurologic progression of X-linked adrenoleukodystrophy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Combined liquid chromatography-tandem mass spectrometry as an analytical method for high throughput screening for X-linked adrenoleukodystrophy and other peroxisomal disorders: preliminary findings

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0421

7 January 2021

Identifiers

DOI

10.1038/NCPNEURO0421

1 reference

PubMed ID

17342190

Dimensions Publication ID

30 July 2017

0 references

1 reference

PubMed ID

17342190